The partnership will allow international manufacturers to use the technologies for the potential development of COVID-19 vaccines, treatments and diagnostics to benefit people living in low- and middle-income countries.
The National Institutes of Health, or NIH, recently announced their collaboration with the World Health Organization, or WHO, and the Medicines Patent Pool to make COVID-19 health technologies available worldwide.
The announcement was made at the second Global COVID-19 Summit on May 5.
The NIH has licensed 11 COVID-19 research tools and early-stage vaccine and diagnostic candidates to the Medicines Patent Pool through WHO's COVID-19 Technology Access Pool, or C-TAP, according to an article from HealthcareFinance.
These licenses will allow international manufacturers to use the technologies for the potential development of COVID-19 vaccines, treatments and diagnostics to benefit people living in low- and middle-income countries.
C-TAP aims to boost the global supply of vaccines, treatments and diagnostics for COVID-19 by facilitating the sharing of intellectual property, knowledge and data with quality-assured manufacturers that have the capacity to scale up production, the report said.
"Controlling COVID-19 globally and addressing future public health threats is only possible if all communities, including the most vulnerable, have access to lifesaving treatments, vaccines and diagnostics," said Health and Human Services Secretary Xavier Becerra, in the report. "Sharing our scientific knowledge and health technologies with C-TAP to foster the development of crucial medical countermeasures is another step we are taking to assist our global partners in our shared fight against this devastating disease."
The agreement will allow for greater access to these technologies with the goal of leading to the development of commercial products that can address current and future public health needs.